Launch | Medicines Patent Pool Strategy 2023-2025
The Medicines Patent Pool (MPP) was honoured to present its Strategy 2023-2025 on Monday 30 January 2023. Since 2010, MPP has signed 34 licences for different health technologies and facilitated access to over 30 billion doses of treatments. Over the next three years, MPP will aim to conclude licences for ten innovative health products and support the introduction of affordable versions of five products that will help to improve the standard of care in LMICs across the different diseases in which MPP works. We will also support technology transfer of mRNA vaccine technology to ten manufacturers. We expect that our licences will allow 30 million people to benefit annually, double from where it stands today and contribute to saving USD 1.2 billion.
Welcome and introduction
- Marie-Paule Kieny, Chair of the MPP Governance Board
- Charles Gore, Executive Director, MPP
- Lav Agarwal, Additional Secretary at the Ministry of Health and Family Welfare of the Government of India
Panel discussion 1 –
Goal 1: Expand access to innovative medicines for infectious diseases
Goal 2: Establish voluntary licensing as an impactful access mechanism for other diseases and conditions
- Philippe Duneton, Executive Director, Unitaid
- Helen McDowell, Head of Government Affairs & Global Public Health, ViiV Healthcare
- Denise Uzoma Ejoh, Chief Executive of Cormode Cancer Foundation, Nigeria
- Cary Adams, Chief Executive Officer, Union for International Cancer Control
Panel discussion 2 –
Goal 3: Facilitate development and access to novel medical technologies
Goal 4: Accelerate equitable access to countermeasures for pandemics and other international health emergencies
Goal 5: Support diversified and sustainable manufacturing capacity
- Nombeko Mpongo, Community Liaison Administrator, Desmond Tutu Health Foundation
- Jay Iyer, Chief Executive Officer, Access to Medicine Foundation
- Rahul Lande, Vice President, International Business, Hetero
- Martin Friede, Coordinator, Initiative for Vaccine Research, World Health Organization
- Erika Placella, Head of Health, Federal Department of Foreign Affairs, Swiss Agency for Development and Cooperation
This exciting new phase centres around five core goals for greater access to vital medicines and health technologies in lower- and middle-income countries. The Strategy also explains how these goals will be achieved, as well as outlining key MPP achievements since its inception in 2010.
Dr Tedros Adhanom Ghebreyesus, the Director-General of the World Health Organization, spoke about the need for a greater global response to reversing inequitable access to vital health medicines and technologies in lower- and middle-income countries. He stressed that MPP’s new Strategy offered a way forward to overcome these inequities.